A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Platelets are small types of blood cells that prevent excessive bleeding. It’s possible to develop low or high platelet counts related to a number of health conditions. Platelets are one of the main ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

Randomized trials of platelet function and genetic testing to guide antiplatelet decisions following PCI have produced notoriously mixed results: now, an updated consensus document aims to fill some ...

Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...